Search Results

Biotech Bay

SanBio Joins the Newly Formed National TBI Registry Coalition (NTRC) as a Founding Member Organization

The SanBio Group today announced it is one of the founding member organizations of the National TBI Registry Coalition (NTRC) in the United States.

December 15, 2021

·

4 min read

Policy

SanBio: Notice Regarding Completion of Approval Filing for Japan SB623 Chronic TBI Program

The SanBio Group hereby announces the completion of an application filing with Japan’s Ministry of Health, Labour, and Welfare for manufacture and marketing approval as a regenerative medicine product for the investigational product SB623, as a treatment for chronic motor deficit from traumatic brain injury.

March 7, 2022

·

5 min read

Biotech Bay

SanBio Announces Publication Comparing Outcome Measures for Persons With Chronic Traumatic Brain Injury in Expert Review of Neurotherapeutics

The SanBio Group, hereby announce that data comparing outcome measures for persons with traumatic brain injury living with chronic motor deficits was published in Expert Review of Neurotherapeutics.

November 1, 2021

·

6 min read

Drug Development

SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology

SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology Publication Affirms SanBio’s Approach to Treating Chronic Traumatic Brain Injury Patients

January 4, 2021

·

6 min read

Medicine doctor team meeting and analysis. Diagnose checking brain testing result with modern virtual screen interface on laptop with stethoscope in hand, Medical technology network connection concept.

Drug Development

Argenx, Pharma Two B, SanBio Present at AAN

Discover what’s in store for today’s presentations at The American Academy of Neurology’s annual meeting, which will include data for a variety of neurological treatments.

April 5, 2022

·

3 min read

·

Hannah Chudleigh

Business

Notice Regarding Business Alliance Between Sanbio and Ocumension in the Research, Development and Commercialization of Innovative Stem Cell Therapies for Ophthalmic Diseases

SanBio Co., Ltd. hereby announces that SanBio has entered into a business alliance with Ocumension Limited.

March 31, 2020

·

3 min read

Business

Bijan Nejadnik, M.D., Appointed as Chief Medical Officer of SanBio

The SanBio Group announced the appointment of Bijan Nejadnik, M.D., as its new Chief Medical Officer in charge of development and regulatory affairs.

May 15, 2019

·

3 min read

Business

SanBio: Joint Research Agreement for SB623 Targeting Dementia

SanBio Company Limited announced it has concluded an agreement with Keio University School of Medicine on joint research for SB623 targeting dementia.

July 23, 2018

·

2 min read

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group.

January 20, 2019

·

2 min read

Biotech Bay

SanBio: SB623, an Investigational Product, Granted Advanced Therapy Medicinal Product Classification by European Medicines Agency

he SanBio Group announced that Advanced Therapy Medicinal Product (ATMP) classification has been granted for SB623 for the treatment of patients with motor deficits arising from Acquired Brain Injury, including traumatic brain injury, ischemic stroke and haemorrhagic stroke.

April 24, 2019

·

4 min read